EMA Lapsed: Tasermity (sevelamer hydrochloride) — Genzyme Europe BV

View source ↗

Summary

EMA has lapsed the marketing authorization for Tasermity (sevelamer hydrochloride) by Genzyme Europe BV for hyperphosphatemia and renal dialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperphosphatemia
• Renal Dialysis-related Hyperphosphatemia

Drugs mentioned

• Tasermity (sevelamer hydrochloride)

Snippet

Status: Lapsed. Therapeutic area: Hyperphosphatemia;Renal Dialysis. MAH: Genzyme Europe BV. Decision date: 15/12/2017